REDWOOD CITY, Calif.
, Jan. 24, 2013
/PRNewswire/ -- myoscience is pleased to announce that their next generation device has received FDA clearance for treatment of peripheral nerve tissue using Focused Cold Therapy for the blocking of pain.
Focused Cold Therapy, myoscience's platform technology, relies upon the well-established science of cryoneuromodulation to precisely deliver cold to peripheral nerve tissue. Nerves treated with this technology undergo a predictable period of dormancy, followed by complete restoration of function.
"This clearance is a significant milestone for our company, paving the way to commercialize our product in the United States. Our engineers have done a remarkable job harnessing the power of cold within a sophisticated yet simple to use device," said Clint Carnell, Chief Executive Officer of myoscience.
The effects of Focused Cold Therapy are immediate, with patients experiencing instant pain relief and the ability to return to normal activities with minimal downtime. The myoscience device delivers a precise treatment to the target tissuethere is no diffusion of effect beyond the selected target.
"The potential of Focused Cold Therapy is to provide treatment options for a wide range of patients seeking safe, effective and immediate pain relief without the systemic risks associated with other therapies," said Dr. Richard Radnovich.
myoscience is a Silicon Valley, California-based medical device company committed to making its breakthrough technology, Focused Cold Therapy, the standard of care in the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction, and the treatment of dermatologic conditions. This technology has also been cleared in the United States for pain management and general surgical use.
Company Contact: Alexandra Mack, (650) 421-0609